Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis
Amy S. Paller MD , Marjolein de Bruin-Weller MD , Danielle Marcoux MD , Eulalia Baselga MD , Vania Oliveira de Carvalho MD , Ledit R.F. Ardusso MD , Suzanne G.M.A. Pasmans MD , Mirna Toledo-Bahena MD, MSc , Cory Rubin MD , Joel C. Joyce MD , Lara Wine Lee MD, PhD , Bryan Adams PhD , Rajan Gupta PhD , Marius Ardeleanu MD , Annie Zhang MD
{"title":"Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis","authors":"Amy S. Paller MD , Marjolein de Bruin-Weller MD , Danielle Marcoux MD , Eulalia Baselga MD , Vania Oliveira de Carvalho MD , Ledit R.F. Ardusso MD , Suzanne G.M.A. Pasmans MD , Mirna Toledo-Bahena MD, MSc , Cory Rubin MD , Joel C. Joyce MD , Lara Wine Lee MD, PhD , Bryan Adams PhD , Rajan Gupta PhD , Marius Ardeleanu MD , Annie Zhang MD","doi":"10.1016/j.jaad.2024.09.046","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The arrival of biologics and small-molecule therapies (eg Janus kinase inhibitors) changed atopic dermatitis treatment, but older systemic treatments continue to be prescribed.</div></div><div><h3>Objective</h3><div>To provide real-world effectiveness, safety, and adherence data for dupilumab, cyclosporine, and methotrexate.</div></div><div><h3>Methods</h3><div>PEDIatric STudy in Atopic Dermatitis (NCT03687359) is a real-world, prospective, observational, 10-year study of children (<12 years) with inadequately controlled moderate-to-severe atopic dermatitis. We report 2-year interim results.</div></div><div><h3>Results</h3><div>Median treatment durations were 8.1, 13.0, and 10.7 months for dupilumab (<em>n</em> = 144), methotrexate (<em>n</em> = 114), and cyclosporine (<em>n</em> = 121), respectively. Dupilumab had numerically greater within-group improvements than methotrexate and cyclosporine in Eczema Area and Severity Index (−12.4∗ vs −5.7∗ and −3.3); body surface area affected (−19.9%∗ vs −11.8%∗ and −8.8%∗); itching (night-time: −2.1∗ vs −0.4 and + 0.1; daytime: −1.5∗ vs +0.1 and + 0.2; ≥6 years); itching/scratching (−3.6∗ vs −1.4∗ and −0.2; <6 years); and Patient-Oriented Eczema Measure (−7.0∗ vs −4.7∗ and −1.5) (∗<em>P</em> < .05 within-group improvements from baseline). Dupilumab had less discontinuations (8.3% vs 28.9% and 43.0%) and adverse event(s) (18.1% vs 29.8% and 31.4%).</div></div><div><h3>Limitations</h3><div>No randomization, placebo, or specified dosages.</div></div><div><h3>Conclusion</h3><div>Dupilumab was associated with numerically greater outcomes and higher adherence than cyclosporine or methotrexate.</div></div>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"92 2","pages":"Pages 242-251"},"PeriodicalIF":12.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0190962224029190","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The arrival of biologics and small-molecule therapies (eg Janus kinase inhibitors) changed atopic dermatitis treatment, but older systemic treatments continue to be prescribed.
Objective
To provide real-world effectiveness, safety, and adherence data for dupilumab, cyclosporine, and methotrexate.
Methods
PEDIatric STudy in Atopic Dermatitis (NCT03687359) is a real-world, prospective, observational, 10-year study of children (<12 years) with inadequately controlled moderate-to-severe atopic dermatitis. We report 2-year interim results.
Results
Median treatment durations were 8.1, 13.0, and 10.7 months for dupilumab (n = 144), methotrexate (n = 114), and cyclosporine (n = 121), respectively. Dupilumab had numerically greater within-group improvements than methotrexate and cyclosporine in Eczema Area and Severity Index (−12.4∗ vs −5.7∗ and −3.3); body surface area affected (−19.9%∗ vs −11.8%∗ and −8.8%∗); itching (night-time: −2.1∗ vs −0.4 and + 0.1; daytime: −1.5∗ vs +0.1 and + 0.2; ≥6 years); itching/scratching (−3.6∗ vs −1.4∗ and −0.2; <6 years); and Patient-Oriented Eczema Measure (−7.0∗ vs −4.7∗ and −1.5) (∗P < .05 within-group improvements from baseline). Dupilumab had less discontinuations (8.3% vs 28.9% and 43.0%) and adverse event(s) (18.1% vs 29.8% and 31.4%).
Limitations
No randomization, placebo, or specified dosages.
Conclusion
Dupilumab was associated with numerically greater outcomes and higher adherence than cyclosporine or methotrexate.
期刊介绍：
The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
